Artiva Biotherapeutics, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Artiva Biotherapeutics halted development of AlloNK (AB-101) following two Grade 5 fatal safety events—one assessed as likely fludarabine toxicity (leukoencephalopathy), another unrelated—and durability data below required thresholds. The company is reducing workforce by ~94% and engaged Leerink Partners to evaluate strategic alternatives including merger, asset sale, or liquidation. Cash position of $319.1M (preliminary, unaudited) as of September 30, 2026.
Why this rating
Lead program terminated after patient deaths; near-total workforce reduction; existential company restructuring. Relative to $15M market cap, clinical failure and strategic uncertainty represent business-ending event.
Tradability signal
SHORT
conviction 45/100 · expected -1.24% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (95 in this cell) moved +1.57% in the called direction over 4 hrs; shrunk for sample size that's a +1.24% edge. Price is up 0.0% since the filing hit EDGAR — market hasn't digested it yet. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $4.20 ▲ 1.05% | at our read · unknown $4.16 | +10 min · unknown $4.24 ▲ 1.80% | +30 min · unknown $4.41 ▲ 6.01% | +1 hr pending | +4 hrs pending |
The stock had already moved -1.04% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.